Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Medicine and Health Sciences
Ambroxol As A Novel Disease-Modifying Treatment For Parkinson's Disease Dementia: Protocol For A Single-Centre, Randomized, Double-Blind, Placebo-Controlled Trial, C. R.A. Silveira, J. Mackinley, K. Coleman, Z. Li, E. Finger, R. Bartha, S. A. Morrow, J. Wells, M. Borrie, R. G. Tirona, C. A. Rupar, G. Zou, R. A. Hegele, D. Mahuran, Penny A. Macdonald, M. E. Jenkins, M. Jog, S. H. Pasternak
Ambroxol As A Novel Disease-Modifying Treatment For Parkinson's Disease Dementia: Protocol For A Single-Centre, Randomized, Double-Blind, Placebo-Controlled Trial, C. R.A. Silveira, J. Mackinley, K. Coleman, Z. Li, E. Finger, R. Bartha, S. A. Morrow, J. Wells, M. Borrie, R. G. Tirona, C. A. Rupar, G. Zou, R. A. Hegele, D. Mahuran, Penny A. Macdonald, M. E. Jenkins, M. Jog, S. H. Pasternak
Medical Biophysics Publications
© 2019 The Author(s). Background: Currently there are no disease-modifying treatments for Parkinson's disease dementia (PDD), a condition linked to aggregation of the protein α-synuclein in subcortical and cortical brain areas. One of the leading genetic risk factors for Parkinson's disease is being a carrier in the gene for β-Glucocerebrosidase (GCase; gene name GBA1). Studies in cell culture and animal models have shown that raising the levels of GCase can decrease levels of α-synuclein. Ambroxol is a pharmacological chaperone for GCase and is able to raise the levels of GCase and could therefore be a disease-modifying treatment for PDD. The …